Browse
Submit Data
Databases
API
Help

Dataset Information

5 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Comparison of intervals between colonoscopic examinations in Familial Colorectal Cancer: The Dutch FAmilial ColorecTal cancer Surveillance study (the FACTS study) Group

ABSTRACT: Background and study aims Five to ten percent of all cases of colorectal cancer (CRC) are caused by a combination of hereditary and environmental factors; these cases are collectively referred to as ‘familial CRC’. Colonoscopic surveillance is recommended for individuals with familial CRC. However, the appropriate screening interval (between colonoscopic examinations) has not yet been determined. The aim of this study was to compare a 3-year with a 6-year screening interval. Who can participate? 500 adults aged 45-65, with a family history of CRC. What does the study involve? Participants will get a colonoscopy at enrollment in the study to determine if they have certain types of polyps (adenomas) that could become cancerous. These will be removed. If participants have 3 or more adenomas, next colonoscopies will be scheduled after 3 and 6 years. If participants have 0, 1 or 2 adenomas, they are randomly assigned to 2 study groups: follow-up colonoscopy in group A will be scheduled after 6 years, while in group B follow-up colonoscopies will be scheduled after 3 and 6 years. Comparisons between the groups A and B will be made for the presence of advanced adenomas (which have a higher potential of becoming cancerous but are not yet cancerous). This will help us define the interval to recommend between 2 colonoscopies.

DISEASE(S): Colorectal Cancer (crc)

PROVIDER: 2424453 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Identification of distinct molecular signatures in AIP mutation-positive familial isolated pituitary adenomas

Project description:The aim of this study was to perform comparative gene expression analysis of AIP mutation-positive, AIP mutation-negative familial and sporadic somatotroph tumours to discover the genes/pathways responsible for the aggressive phenotype. Gene expression analysis was performed on 25 pituitary samples (five normal pituitary, six AIPpos GH, three AIPneg GH, four sporadic GH, two AIPneg familial NFPA and five sporadic NFPA adenomas) using the Affymetrix human Gene Chip HG-U133 Plus 2.0 array.

2018-04-13 | GSE63357 | GEO

Expression data of Familial adenomatous polyposis (FAP) organoids

Project description:FAP is an autosomal-dominant inherited disease caused by germline mutations in the APC gene 1. Two major FAP phenotypes, CFAP and AFAP, can be distinguished based on polyp numbers and age of onset. CFAP is characterized by the presence of hundreds to thousands of polyps. About half of these patients develop adenomas by age 15, and 95% develop adenomas by age 35. AFAP patients exhibit a milder phenotype than CFAP patients; AFAP is characterized by fewer polyps, later adenoma onset, and lower CRC risk. We used microarrays to analyze the expression profiles of organoids established from three CFAP and two AFAP patients.

2019-12-31 | GSE109812 | GEO

SNP data of Familial adenomatous polyposis (FAP) organoids

Project description:FAP is an autosomal-dominant inherited disease caused by germline mutations in the APC gene 1. Two major FAP phenotypes, CFAP and AFAP, can be distinguished based on polyp numbers and age of onset. CFAP is characterized by the presence of hundreds to thousands of polyps. About half of these patients develop adenomas by age 15, and 95% develop adenomas by age 35. AFAP patients exhibit a milder phenotype than CFAP patients; AFAP is characterized by fewer polyps, later adenoma onset, and lower CRC risk. We used microarrays to analyze chromosome abberation of organids established from FAP patients.

2019-12-31 | GSE109813 | GEO

Mutated in Colorectal Cancer (MCC): A Novel Centrosomal Protein Involved in Intestinal Homeostasis and Disease

Project description:Mutated in Colorectal Cancer (MCC) is a candidate tumor suppressor gene reported to be somatically mutated in the inherited colorectal cancer (CRC) syndrome Familial Adenomatous Polyposis. Additionally, MCC deletion and loss-ofheterozygosity have also been reported as a common event in human CRC. However,to date, more than 28 years since its discovery, the mechanisms by which MCC contributes to intestinal cancer development as well as its function during normal intestinal tissue homeostasis remain unknown.

2023-07-29 | PXD035614 | JPOST Repository

Gene expression profiling of colorectal normal mucosa, adenoma and adenocarcinoma tissues

Project description:Approximately two decades ago, Vogelstein and Fearon proposed the adenoma-carcinoma sequence of sporadic CRC development and illustrated the accumulation of genetic alterations during the stepwise progression, thereby providing a guideline for clinical practice. Although the detection and excision of precancerous lesions could prevent colorectal cancer and reduce mortality, 6% of adenomas will ultimately develop into colorectal cancer. Thus, this genetic model for colorectal tumorigenesis may not completely reflect the complex essence of the disease and whether the mode of initiation of the events in the multistep progression affects the outcome of CRC is still unknown. In this study, mRNA and miRNA expression profiling was performed with human colorectal tissues, including normal mucosa, adenoma and adenocarcinoma. Then, an integrated approach was adopted to establish the regulatory interaction networks that were correlated with colorectal carcinogenesis. Finally, a 55-gene signature whose expression was down-regulated in precancerous lesions compared to normal tissue was identified as a potential early indicator of CRC survival. The results suggested that genes related to immunity and homeostasis played a critical role in protection against adenoma initiation and that the altered molecular events that influence colorectal cancer prognosis may be set in an early, precancerous stage. Four types of human colorectal tissues were selected by colonoscopic resection or colorectal surgery, including 12 normal mucosae, 21 low-grade adenomas (mild or moderate atypical hyperplasia), 30 high-grade adenomas (severe atypical hyperplasia or carcinoma in situ) and 25 adenocarcinomas. Gene expression profiling analysis of these samples was performed using Agilent 4x44K human whole genome gene expression microarray (G4112F).

2015-10-16 | E-GEOD-41657 | biostudies-arrayexpress

MicroRNA expression profiling of colorectal normal mucosa, adenoma and adenocarcinoma tissues

Project description:Approximately two decades ago, Vogelstein and Fearon proposed the adenoma-carcinoma sequence of sporadic CRC development and illustrated the accumulation of genetic alterations during the stepwise progression, thereby providing a guideline for clinical practice. Although the detection and excision of precancerous lesions could prevent colorectal cancer and reduce mortality, 6% of adenomas will ultimately develop into colorectal cancer. Thus, this genetic model for colorectal tumorigenesis may not completely reflect the complex essence of the disease and whether the mode of initiation of the events in the multistep progression affects the outcome of CRC is still unknown. In this study, mRNA and miRNA expression profiling was performed with human colorectal tissues, including normal mucosa, adenoma and adenocarcinoma. Then, an integrated approach was adopted to establish the regulatory interaction networks that were correlated with colorectal carcinogenesis. Finally, a 55-gene signature whose expression was down-regulated in precancerous lesions compared to normal tissue was identified as a potential early indicator of CRC survival. The results suggested that genes related to immunity and homeostasis played a critical role in protection against adenoma initiation and that the altered molecular events that influence colorectal cancer prognosis may be set in an early, precancerous stage. Four types of human colorectal tissues were selected by colonoscopic resection or colorectal surgery, including 15 normal mucosae, 39 low-grade adenomas (mild or moderate atypical hyperplasia), 20 high-grade adenomas (severe atypical hyperplasia or carcinoma in situ) and 33 adenocarcinomas. MicroRNA expression profiling analysis of these samples was performed on Agilent 8Ã16K Human miRNA Microarray V3 (G4470C).

2015-10-16 | E-GEOD-41655 | biostudies-arrayexpress

Identifying Patients With Hereditary and Familial Colorectal Cancer by Using an Online Risk Tool

Project description:In this trial the investigators will evaluate the effectiveness of the implementation of a digital familial risk questionnaire in the detection of CRC patients with hereditary or familial CRC. This will be done using a stepped wedge design with 5 participating hospitals for a duration of 1.5 years. A comparison is made between an intervention phase (offering the online risk assessment questionnaire) and a control phase (hospital-based standard practice for the detection of CRC patients with hereditary or familial CRC, informed by the referral criteria that are being used in the intervention group). All patients with a diagnosis of CRC who have a first appointment at the CRC outpatient clinic will be included. The primary outcome is the percentage of all included patients who receive a recommendation for regular surveillance colonoscopies for himself/herself and/or relatives, provided by a clinical geneticist. Data from clinical geneticists is being used to answer this question.

| 2205406 | ecrin-mdr-crc

Comparing autofluorescence endoscopy and white light video endoscopy for surveillance of patients with familial colorectal cancer.

Project description:Interventions: Colonoscopic surveillance with both WLE and AFE in high risk patients (Lynch syndrome or familial colorectal cancer). In case of the detection of colorectal lesions (adenoma, colorectal cancer or hyperplasia) these lesions were removed by polypectomy. AFE was compared to WLE (active control) with respect to the diagnostic yield (detection of colorectal lesions). Primary outcome(s): The difference between WLE and AFE for detection of adenomatous lesion or CRC during colonoscopy in patient with HNPCC or familial CRC. Study Design: Non-randomized controlled trial, Open (masking not used), Active, Crossover

| 16175 | ecrin-mdr-crc

Identifying patients with hereditary and familial colorectal cancer by using an online risk tool

Project description:Intervention: offering an online risk assessment questionnaire to CRC patients, to facilitate the detection of CRC patients with hereditary or familial CRC Control: Hospital-based standard practice for the detection of CRC patients with hereditary or familial CRC, informed by the referral criteria that are being used in the intervention group Primary outcome(s): Percentage of all included patients who receive a recommendation for regular surveillance colonoscopies for himself/herself and/or relatives, provided by a clinical geneticist. Study Design: Non-randomized controlled trial, Open (masking not used), Active, Crossover

| 19677 | ecrin-mdr-crc

Molecular characterization of colorectal adenomas reveals POFUT1 as a candidate driver of tumor progression

Project description:Colorectal adenomas are benign precursor lesions of colorectal cancer (CRC) that arise from normal epithelium1. The prevalence of adenomas in the large intestine is much higher than the incidence of cancer implying that the majority of adenomas will never progress to CRC4. In clinical practice, adenomas detected during colonoscopy are completely removed, and consequently the natural history of disease disrupted. Based on the prevalence of focal cancer in endoscopically removed adenomas, it is estimated that only 5% of adenomas will eventually progress to CRC. The aim of the present study was to characterize adenomas at low and high risk of progressing to cancer by extensive molecular profiling at DNA, RNA, and protein level, allowing to examine the biological processes in which they differ and to discover putative drivers of early colorectal tumor development.

2019-08-22 | PXD012254 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data